Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - conjugated estrogens - prolonged-release tablet - 0.625 milligram(s) - natural and semisynthetic estrogens, plain; conjugated estrogens

European Union - English - EMA (European Medicines Agency)

pfizer europe ma eeig - oestrogens conjugated, bazedoxifene - postmenopause - conjugated estrogens and bazedoxifene - duavive is indicated for:treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate.the experience treating women older than 65 years is limited.

United States - English - NLM (National Library of Medicine)

conju inc - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), arbutin (unii: c5ina23hxf) (arbutin - unii:c5ina23hxf), adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - titanium dioxide 10.15 ml in 100 ml

United States - English - NLM (National Library of Medicine)

conju inc - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), enzacamene (unii: 8i3xwy40l9) (enzacamene - unii:8i3xwy40l9), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), avobenzone (unii: g63qqf2nox) (avobenzone - unii:g63qqf2nox), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - octinoxate 0.075 ml in 1 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - conjugated estrogens, quantity: 0.3 mg - tablet, film coated - excipient ingredients: sucrose; hyprolose; macrogol 400; carnauba wax; hypromellose; lactose monohydrate; microcrystalline cellulose; magnesium stearate; calcium phosphate; powdered cellulose; titanium dioxide; propylene glycol; purified water; isopropyl alcohol; polysorbate 80; quinoline yellow aluminium lake; indigo carmine aluminium lake - oestrogens with or without progestogens should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman. 1. premarin is indicated as replacement therapy for oestrogen deficiency states associated with climacteric manifested by: a) moderate to severe vasomotor symptoms associated with oestrogen deficiency in natural and surgical menopause (sweating, hot flushes). periodic re-evaluation with a view to short term treatment is recommended. b) atrophic vaginitis. when prescribing solely for the treatment of symptoms of vaginal atrophy, topical vaginal products should be considered. there is no evidence that oestrogens are effective for anxiety or depression without associated vasomotor symptoms, and they should not be used to treat such conditions. 2. premarin is indicated for the prevention of postmenopausal osteoporosis in select patients. when prescribed solely for the prevention of postmenopausal osteoporosis, therapy should only be prescribed for women who are at high risk of osteoporosis and future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of osteoporosis. life style modifications and the risk benefit profile of premarin should be taken into careful consideration and discussed with the patient, to allow the patient to make an informed decision prior to prescribing. (see precautions and dosage and administration). 3. hypoestrogenic states e.g. female hypogonadism, primary ovarian failure or female castration. see boxed warning, particularly when considering premarin for long-term usage.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - medroxyprogesterone acetate; conjugated oestrogens - oral tablet - 10mg ; 625microgram

United States - English - NLM (National Library of Medicine)

conju inc - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), arbutin (unii: c5ina23hxf) (arbutin - unii:c5ina23hxf), adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) -

United States - English - NLM (National Library of Medicine)

conju inc - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51), enzacamene (unii: 8i3xwy40l9) (enzacamene - unii:8i3xwy40l9), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), avobenzone (unii: g63qqf2nox) (avobenzone - unii:g63qqf2nox), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) -

United States - English - NLM (National Library of Medicine)

conju inc - tocopherol (unii: r0zb2556p8) (tocopherol - unii:r0zb2556p8) - skin protectant apply to the skin and wash away

United States - English - NLM (National Library of Medicine)

conju inc - tocopherol (unii: r0zb2556p8) (tocopherol - unii:r0zb2556p8) - skin protectant apply proper amount to the skin and rinse it with cold or lukewarm water.